Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Toho: Solid Growth in Sales, Profits
June 5, 2006
- Avonex, Baraclude Recommended for Approval
June 5, 2006
- Hokuyaku, Takeyama to Integrate Business in September
June 5, 2006
- Mr Niwa Offers 8 Proposals for Social Security Reform
June 5, 2006
- GL for Uterine Corpus Cancer to Be Issued this Autumn
May 29, 2006
- Kissei: Pharma Segment Posts Declines in Sales, Profits
May 29, 2006
- REGULATORY NEWS IN BRIEF
May 29, 2006
- Mr Shoda Lays Out Reorganization Plan: Daiichi Sankyo
May 29, 2006
- Nippon Shinyaku: Mild Pollen Season Hits Sales, Profits
May 29, 2006
- JGPMA Business Plan Outlined by President Yoshida
May 29, 2006
- Pfizer to Launch Detrusitol for OAB in June
May 29, 2006
- Torii: Declines in Sales and Profits
May 29, 2006
- JGPMA to Propose "Drug Benefit Standard Prices System"
May 29, 2006
- Banyu to Re-launch Nu-lotan
May 29, 2006
- ASKA: Higher Cost Ratio Results in Profit Slump
May 29, 2006
- GENERIC NEWS IN BRIEF
May 29, 2006
- Combined Sales, Profits of Top 10 Companies Up in FY2005
May 29, 2006
- Toyama Chemical: Pharma Div. Sales Down 8.4%
May 29, 2006
- Metabolic Syndrome Estimated to Affect 9.4 Mil. Japanese Over 40
May 29, 2006
- Astellas: Stronger Sales, Profits Driven by Overseas Growth
May 29, 2006
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…